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| INTRODUCTION
Each year in the United States (US), venous thromboembolism (VTE) affects an estimated 900 000 people and is responsible for approximately 60 000-100 000 deaths. 1 The annual cost of VTE events in the US has been conservatively estimated at $7-10 billion (in 2014 dollars) and is expected to increase with upward trends in per patient costs (primarily driven by increased hospitalization costs) and in total patient number, which is expected to double to 1.82 million by 2050. [2] [3] [4] The two major subtypes of VTE are deep vein thrombosis (DVT) and pulmonary embolism (PE). Patients who have had their first VTE episode have increased risk of recurrence, [5] [6] [7] [8] [9] with the risk being highest in the first few months after the initial episode and remaining high through the first year. 10 About a quarter of patients will have a recurrent episode within 5 years of their initial VTE episode and 30% are expected to have a recurrent episode within 10 years. 10 Although anticoagulant therapy is recognized as the standard of care for treatment and prophylaxis against VTE, there is still uncertainty over the optimal duration of treatment as long-term use of anticoagulants is associated with reduced VTE recurrence risk but also increased bleeding risk. 11, 12 Current guidelines from the American College of Chest Physicians (ACCP) recommend anticoagulant treatment for at least 3 months and suggest extended anticoagulant therapy beyond 3 months for patients with a first unprovoked VTE who have low or moderate bleeding risk. 11, 12 Rivaroxaban, an oral direct factor Xa inhibitor anticoagulant indicated for acute and extended treatment of VTE, 13 has been demonstrated as a viable alternative therapy to traditional vitamin K antagonist (VKA) therapy with advantages of minimal drug and food interactions and no requirement for routine coagulation monitoring. [13] [14] [15] Findings from a pair of phase III clinical trials have
shown that extended treatment with rivaroxaban for an additional 6-12 months is safe and effective to decrease VTE recurrence risk in patients with VTE who have previously completed 6 or 12 months of anticoagulant therapy. 14, 16 The double-blind placebo-controlled EINSTEIN-Extension trial (EINSTEIN-EXT) reported a VTE recurrence rate of 1.3% in patients receiving extended treatment with once-daily 20 mg rivaroxaban vs 7.1% in patients receiving placebo, representing a statistically significant 82% relative risk reduction (P < .001).
17
A marginal increase in the rate of major bleeding that did not reach statistical significance was observed in the rivaroxaban cohort (0.7% vs 0% for placebo; P = .11). More recently, data from the double-blind EINSTEIN-CHOICE trial reported VTE recurrence rates of 1.5% and 1.2% in patients receiving up to 12 months of extended treatment with once-daily 20 mg or 10 mg rivaroxaban respectively vs 4.4% for patients receiving once-daily 100 mg aspirin, representing statistically significant 66% and 74% relative risk reductions (P < .001 for both).
16
Observed rates of major bleeding were comparable at 0.5% and 0.4% 5, 6, 8 the extent to which the finding in the overall VTE population could be applicable to the subset of patients with unprovoked VTE remains unclear.
The current study is an extension of our previous claims study and aims to assess the risk of recurrent VTE and major bleeding in a real-world setting among US patients who had their first unprovoked VTE and continued (also noted as extended treatment) or discontinued rivaroxaban therapy after a minimum duration of treatment. For the main analyses, the minimum duration of treatment was set at 3 months per ACCP guideline recommendations, 12 and a sensitivity analysis was adopting an alternative minimum duration of treatment of 6 months as used in the EINSTEIN-EXT and EINSTEIN-CHOICE trials.
14,16 
| MATERIALS AND METHODS

| Data source
Essentials
• Clinical trials demonstrated the gain of extended anticoagulation among patients with VTE.
• In a real-world setting, we evaluated outcomes of extended rivaroxaban use for unprovoked VTE.
• Extended rivaroxaban treatment lowered the risk of recurrent VTE among unprovoked VTE patients.
• Extended rivaroxaban treatment was not associated with increased risk of major bleeding.
approximately 100 employers and a number of health plans, while the latter focuses on patients aged 65 years old and above with Medicare coverage plus employer-paid commercial plans. Institutional review board approval was not required for this study due to the preexisting and de-identified nature of the data.
| Study design
A retrospective longitudinal study design was used in this study. bleeding.
15
Patients who had used anticoagulant agents during baseline, had a diagnosis of atrial fibrillation or major bleeding event during baseline, or had recurrent VTEs between the index VTE and the index date were excluded. Sensitivity analyses were conducted among patients who received at least 6 months of continuous rivaroxaban treatment.
| Outcome measures
The study endpoints include recurrent VTE (DVT or PE) requiring hospitalization and major bleeding event requiring hospitalization. 
| Statistical analyses
Patient demographics and baseline clinical characteristics of both cohorts were reported and compared using descriptive statistics.
Categorical variables were summarized with frequencies and proportions, continuous variables were summarized with means, standard deviations, and medians, and differences in baseline variables between cohorts were assessed using standardized differences (≥10% indicating imbalance between cohorts).
23
To assess the relationship between continued treatment and outcomes (ie, recurrent VTEs and major bleeding events), KaplanMeier curves adjusted with inverse probability of treatment weights (IPTWs) were compared between cohorts. The IPTWs were used to control for baseline confounding and potential selection bias, 24 and
were estimated in two steps. First, a multivariate logistic regression model was conducted to estimate the probability (ie, the propen- 
| RESULTS
| Baseline patient characteristics
Among the 4814 unprovoked VTE patients who had received initial treatment with rivaroxaban for at least 3 months, 3763 (78.2%) and 1051 (21.8%) patients formed the continued and discontinued cohorts, respectively ( Figure 1 ). Patient baseline characteristics between cohorts are compared in Tables 1 and 2 . The mean observation period was 160 days and 178 days in the continued cohort and the discontinued cohort, respectively. Continued cohort patients were older, had a lower proportion of female patients, more likely to have an initial PE, have more hospitalizations within the baseline period, had slightly higher RIETE bleeding scores, and had higher Quan-CCI scores compared with discontinued cohort patients. After weighting, the two cohorts had well-balanced baseline characteristics (Tables 1 and 2 ). (Figure 2 ). The difference of KM rates between cohorts increased slightly over time. The analysis by types of recurrent VTE showed that patients in the continued cohort had a significantly lower rate of recurrent PE at 12 months compared to those in the discontinued cohort (0.52% vs. 1.52%, P = .005), while the rate of the recurrent DVT did not differ significantly between the two cohorts (rates at 12 months, continued and discontinued: 0.93% and 1.09%, P = .630).
| Major bleeding events
In the weighted population, 30 patients with 37 major bleeding events were identified at 12 months of follow-up. Of these events, 21 were gastrointestinal, four were genitourinary, one was cerebral, and 11 were other bleeding. No statistically significant differences in the rates of major bleeding were observed between cohorts. The rates of major bleeding in the continued and the discontinued cohort were 0.51% and 0.72% at 3 months (P = .367), 0.79% and 0.72% at 6 months (P = .756), and 1.06% and 1.13% at 12 months (P = .780), respectively ( Figure 3 ).
| Sensitivity analysis
A sensitivity analysis was conducted among the 2557 patients who received rivaroxaban treatment for at least 6 months. Comparisons of patient baseline characteristics between the discontinued (N = 793) and continued cohort (N = 1764) are presented in Table S1 . This analysis also showed that the continued treatment was associated with a reduced risk of recurrent VTE with no significant difference in major bleeding ( Figures S1 and S2 ).
| DISCUSSION
Currently, there is no clear consensus on the optimal time that unprovoked VTE patients should remain on anticoagulants as long-term use of anticoagulants will reduce the risk of recurrence but may increase the risk of bleeding. The current study assessed the impact of the 3-or 6-month extended treatment with rivaroxaban on the risk of recurrent VTE and major bleeding among patients with unprovoked
VTEs in the real-world settings using US-based claims databases.
Compared with those who stopped rivaroxaban at 3 months, patients who received rivaroxaban beyond 3 months (ie, the continued cohort) had a 44% lower risk of recurrent VTE at 12 months (1.45% vs 2.60%, P = .023). The number needed to treat for 12 months to avoid one recurrent VTE was 87. Similarly, the analysis of continuous treatment with rivaroxaban for at least 6 months (vs stopped at 6 months)
showed that patients in the continued cohort had a 65% lower risk of recurrent VTE at 12 months (from 4.62% vs 1.64% for discontinued vs continued cohorts, P = .002). Both 3-and 6-month analyses showed no statistically significant differences in the risk of major bleeding event between the continued and discontinued cohorts.
The stratified analysis by type of recurrent VTE (PE or DVT) in the current study demonstrated that patients in the continued cohort had a significantly lower risk of recurrent PE compared to those in the discontinued cohort. Although the rate of recurrent DVT was also lower in the continued cohort, this difference was not statistically significant. This may be explained by insufficient statistical power to detect an effect due to the short duration of follow-up (up to 12 months) and by the potential underestimation of the number of recurrent VTEs due to using a hospitalization-based approach to identify recurrent VTEs (ie, only VTEs diagnosed in hospitalizations were defined as recurrent VTEs). Since patients with DVT are more likely to be treated in outpatient settings than patients with PE, underestimation of recurrent events using a hospitalization-based approach may have a more profound impact on the rate estimation of recurrent DVT than recurrent PE.
The findings in the current study indicating a lower risk of recurrent VTE among patients with unprovoked VTE who received the extended treatment with rivaroxaban are consistent with that reported in our previous study conducted among patients with VTE. Specifically, in the 3-month analysis, the relative risk reduction for recurrent VTE at 12 months was 35% (from 3.01% to 1.97% for discontinued vs continued cohorts, P = .017) among patients with VTE (ie, provoked and unprovoked VTE), compared to 44% observed in our study among patients with unprovoked VTE. Likewise, the relative risk reduction in the 6-month sensitivity analysis was also similar, with 54% (from 3.70% to 1.72% for discontinued vs continued cohorts, P = .024) observed among the overall VTE population and 65% observed in the current study. 18 In addition, as with the current study, our previous study did not find a statistically significant difference in the risk for major bleeding between cohorts.
18
Our findings on the association between extended treatment beyond 3 months and a low risk of recurrent VTE without an increasing risk of major bleeding support the ACCP suggestion of using extended anticoagulant therapy over 3 months among patients who have had their first unprovoked VTE and who have low or moderate bleeding risk. 11 Moreover, the finding in our sensitivity analysis on the association between the extended treatment beyond 6 months and a low risk of recurrent VTE are consistent with the EINSTEIN-EXT and EINSTEIN-CHOICE trials. The relative risk reduction of recurrent VTE event at 12 months was 65% lower for those who continued treatment vs discontinued in our study. The corresponding risk reduction was 82% in EINSTEIN-EXT (rivaroxaban vs. placebo), and about 70%
in EINSTEIN-CHOICE (rivaroxaban vs. aspirin). 14, 16, 25 In both 3-month and 6-month analyses, rates of major bleeding events were low and did not differ significantly between the two cohorts (ie, continued and discontinued). Given the short duration of follow-up (up to 12 months) in our study, insufficient statistical power may explain the inability to detect a significant association of extended treatment with risk of major bleeding. Another possibility is that a potential "reverse causation" may distort the estimated association as patients in the discontinued cohort might have been taken off therapy due to early symptoms of bleeding before the index date and subsequently had a major bleeding event. Therefore, our study may overestimate the rate of major bleeding events in the discontinued cohort in the early period of follow-up and thus diminish the difference in the risk of major bleeding between cohorts. However, with limited information on clinical factors in a claims database, we were not able to test this "reverse causation" hypothesis. Regarding major bleeding events, the non-significant rate difference estimated from our 6-month analysis was smaller than the rate difference reported in the EINSTEIN-EXT trial but similar to that in the EINSTEIN-CHOICE trial, although the level of events was higher (our study: 1.51% vs. 
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This study has a number of limitations. First, claims databases are subject to billing inaccuracies or incomplete coding. Second, the actual consumption of rivaroxaban and the duration of treatment may be overestimated since no information is available to assess whether the medication was taken as prescribed. Third, not capturing the recurrent VTE diagnosed in outpatient settings may have underestimated the rate of recurrent VTE and major bleeding, particularly for recurrent DVT, which are likely to be diagnosed and treated in outpatient settings. However, since the extent of event underestimation may be the same across cohorts, such detection bias may be unlikely to affect our estimates on the rate differences.
Fourth, death is not available in the claims data used in this study and we were not able to assess its potential impact on our findings.
Finally, as with all observational studies, our study results may be subject to unmeasured confounders, such as the potential difference in patients' severity of illness.
Despite the described limitations, the current study provides realworld evidence on the benefits and risks of extended anticoagulation be published and agreed to be accountable for all aspects of the study.
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